Gefurulimab outperformed a placebo in easing gMG symptoms in a clinical trial involving over 250 patients positive for anti-AChR antibodies.| Myasthenia Gravis News
The anti-inflammatory therapy telitacicept for myasthenia gravis was granted orphan drug status in the EU by the European Medicines Agency.| Myasthenia Gravis News
Vor Bio signed an exclusive license agreement to develop and market Remegen’s telitacicept for MG outside China, Hong Kong, Macau, and Taiwan.| Myasthenia Gravis News
Thymectomy led to a long-term reduction in the levels of immune T-cells and to temporary changes in cytokine levels in MG patients.| Myasthenia Gravis News
The FDA has approved once-daily zilucoplan as Zilbrysq for adults with generalized MG who are positive for antibodies targeting AChR.| Myasthenia Gravis News
Study data show long-term treatment with Zilbrysq led to sustained reductions in disease severity in generalized myasthenia gravis patients.| Myasthenia Gravis News
Treatment with nipocalimab in gMG patients led to significant reductions in disease severity, per top-line data from a pivotal Phase 3 trial.| Myasthenia Gravis News
Rituximab is an antibody-based therapy that may be used off-label in patients with certain types of myasthenia gravis.| Myasthenia Gravis News
A 64-year-old woman with dropped head syndrome was found to have a form of MG with antibodies against MuSK, and weak spine muscles.| Myasthenia Gravis News
Rituximab isn't officially approved for MG, but is used off-label when standard treatments fail, such as patients with anti-MuSK antibodies.| Myasthenia Gravis News
More than a quarter of gMG patients wait more than one year to receive an accurate diagnosis, according to study of five European countries.| Myasthenia Gravis News
An open-label, multicenter Phase 2 clinical trial will test KYV-101 in people with refractory MG and positive for self-reactive antibodies.| Myasthenia Gravis News
Vyvgart is an approved infusion treatment for adults with generalized myasthenia gravis who are AChR-antibody positive.| Myasthenia Gravis News
Rystiggo is a myasthenia gravis treatment for adults with generalized MG. It's administered as an injection.| Myasthenia Gravis News
Batoclimab is an experimental antibody therapy being developed for generalized myasthenia gravis, along with other autoimmune disorders.| Myasthenia Gravis News
Getting a correct myasthenia gravis diagnosis may require a series of blood, nerve, muscle, and imaging tests.| Myasthenia Gravis News
Treatment with telitacicept for almost six months lessened disease activity in gMG adults positive for anti-AChR antibodies, per a study.| Myasthenia Gravis News
Soliris (eculizumab) is an infusion therapy approved for treating adults with generalized myasthenia gravis.| Myasthenia Gravis News
Muscle weakness and fatigue are hallmark symptoms of myasthenia gravis (MG), an autoimmune disorder. MG symptoms may come and go.| Myasthenia Gravis News
Generalized myasthenia gravis patients with mild muscle weakness saw more relief after surgery than those with moderate or severe weakness.| Myasthenia Gravis News
Remegen enrolled the first U.S. patient in a Phase 3 trial testing the safety and efficacy of telitacicept for generalized myasthenia gravis.| Myasthenia Gravis News
Soliris effectively eased symptoms and reduced the need for other medications in adults with MG in a clinical practice setting, data show.| Myasthenia Gravis News
Into-the-vein treatment with Vyvgart (efgartigimod alfa) resolved an MG crisis in a man who had failed to respond to prior treatments.| Myasthenia Gravis News
Myasthenia gravis is a neuromuscular disease characterized by weakness and fatigue that can affect muscles involved in voluntary movements.| Myasthenia Gravis News